NEW YORK (GenomeWeb News) — Bruker BioSciences today said first-quarter revenues increased 16 percent as R&D spending rose 11 percent and profit grew 19 percent.
Total receipts for the three months ended March 31 increased to $110.5 million from $94.9 million year over year.
Product revenue increased 14 percent to $95.4 million; service revenue increased 43 percent to $15 million; and “other” revenue contracted 76 percent to $154,000.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.